Incyte Corporation vs Lennar Corporation — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.65B), while Lennar Corporation trades at $87.48 (market cap $20.57B). The key difference: Incyte Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.34% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LEN | |
|---|---|---|
Market Cap | $24.65B | $20.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $142.40 |
52-Week Low | $81.61 | $81.84 |
Enterprise Value | $20.15B | $24.45B |
Dividend Yield | — | 2.34% |
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.
The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.
No Aura AI signal available yet.
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →